Gotovax AB, founded in 1997, is a biopharmaceutical company focused on development and testing of primarily oral vaccines against bacterial gastrointestinal infections. Gotovax and partners developed an internationally widely licensed oral vaccine against Vibrio cholerae and enterotoxigenic Escherichia coli (ETEC)-induced diarrhoea (Dukoral®).
In collaboration with other parties, Gotovax is developing a multivalent oral vaccine against ETEC diarrhoea with reported highly promising results in phase I clinical testing. Gotovax is also engaged in the development of a further improved oral cholera vaccine.
Gotovax has developed a candidate oral whole-cell vaccine against Helicobacter pylori in the form of formalin-killed Vibrio cholerae bacteria engineered to contain large amounts of one (or more) protective Helicobacter pylori antigen(s) and optionally also a specific intestine-binding protein to promote vaccine immunogenicity after oral administration. In collaboration with university scientists, Gotovax has developed recombinant Vibrio cholerae strains that can be induced to express high amounts of recognized protective Helicobacter pylori vaccine antigens.
The lead participants from Gotovax are;
Professor Jan Holmgren, MD, PhD, CEO and Head of Research and Development
Professor Ann-Mari Svennerholm, MD, PhD, Head of Vaccine Characterisation and Clinical Studies